ReNeuron Group Plc (OTCMKTS:RNUGF)’s share price traded up 3.8% during trading on Tuesday . The stock traded as high as $1.91 and last traded at $1.91, 270 shares changed hands during mid-day trading. An increase of 20% from the average session volume of 225 shares. The stock had previously closed at $1.84.
Several analysts have weighed in on RNUGF shares. ValuEngine raised shares of ReNeuron Group from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 15th. Zacks Investment Research raised shares of ReNeuron Group from a “sell” rating to a “hold” rating in a report on Tuesday, December 10th.
The firm has a 50-day moving average of $1.78 and a 200-day moving average of $2.28.
ReNeuron Group Company Profile (OTCMKTS:RNUGF)
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
Featured Story: How much money do you need to begin day trading?
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.